Volunteer studies investigating the safety and efficacy of live oral El Tor Vibrio cholerae O1 vaccine strain CVD 111

American Journal of Tropical Medicine and Hygiene

Volumn 56, Issue 5, 1997, Pages 533-537

  Tacket, Carol O ^a   Kotloff, Karen L ^a   Losonsky, Genevieve ^a   Nataro, James P ^a   Michalski, Jane ^a   Kaper, James B ^a   Edelman, Robert ^a   Levine, Myron M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; CHOLERA VACCINE; CVD 111 CHOLERA VACCINE; LIVE VACCINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHOLERA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFECTION PREVENTION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; VIBRIO CHOLERAE;

BACTERIA (MICROORGANISMS); EL TOR VIBRIO; VIBRIO CHOLERAE; VIBRIO CHOLERAE O1 BIOVAR ELTOR;

EID: 0030918463     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1997.56.533     Document Type: Article

References (17)

1. Levine MM, Tacket CO, 1995. Live oral vaccines against cholera. Ala'Aldeen D, Hornmaeche C, eds. Molecular and Clinical Aspects of Bacterial Vaccine Development. Chicester: John Wiley and Sons, 233-258.
2. Clemens JD, van Loon E Sack DA, Rao MR, Ahmed F, Chakraborty J, Kay BA, Khan MR, Yunus M, Harris JF, Svennerholm A-M, Holmgren J, 1991. Biotype as determinant of natural immunising effect of cholera. Lancet 337: 883-884.
3. Taylor DN, Killeen KP, Hack DC, Kenner JR, Coster TS, Beattie DT, Ezzell J, Hyman T, Trofa A, Sjogren MH, Friedlander A, Mekalanos JJ, Sadol JC, 1994. Development of a live, oral, attenuated vaccine against El Tor cholera. J Infect Dis 170: 1518-1523.
4. Kenner JR, Coster TS, Taylor DN, Trofa AF, Barrer-Oro M, Hyman T, Adams JM, Beattie DT, Killeen KP, Spriggs DP, Mekalanos JJ, Sadoff JC, 1995. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J Infect Dis 172: 1126-1129.
5. Fasano A, Baudry B, Pumplin DW, Wasserman SS, Tall BD, Ketley JM, Kaper JB, 1991. Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc Natl Acad Sci USA 88: 5242-5246.
6. Trucksis M, Galen JE, Michalski J, Fasano A, Kaper JB, 1993. Accessory cholera enterotoxin (ACE), the third toxin of a Vibrio cholerae virulence cassette. Proc Natl Acad Sci USA 90: 5261-5211.
7. Person GDN, Woods A, Chiang SL, Mekalanos JJ, 1993. CTX genetic element encodes a site-specific recombination system and an intestinal colonization factor. Proc Natl Acad Sci USA 90: 3750-3754.
8. Michalski J, Galen JE, Fasano A, Kaper JB, 1993. CVD 110, an attenuated Vibrio cholerae O1 EI Tor live oral vaccine strain. Infect Immun 61: 4462-4468.
9. Tacket CO, Losonsky G, Nataro JP, Cryz, SJ, Edelman R, Fasano A, Michalski J, Kaper JB, Levine MM, 1993. Safety, immunogenicity, and transmissibility of live oral cholera vaccine candidate CVD 110, Δctx Δzot Δace derivative of El Tor Ogawa Vibrio cholerae. J Infect Dis 168: 1536-1540.
10. Levine MM, Black PE, Clements ML, Nalin DR, Cisneros L, Finkelstein RA, 1981. Volunteer studies in development of vaccines against cholera and enterotoxigenic Escherichia coli: a review. Holme T, Holmgren J, Merson MEI, Molby R, eds. Acute Enteric Infections in Children: New Prospects for Treatment and Prevention. Amsterdam: Elsevier/North-Holland Biomedical Press, 443-459.
11. Tacket CO, Losonsky G, Nataro JP, Wasserman SS, Cryz SJ, Edelman R, Levine MM, 1995. Extension of the volunteer challenge model to study South American cholera in a population of volunteers with predominantly blood group antigen O. Trans R Soc Trop Med Hyg 89: 75-77.
12. Clements ML, Levine MM, Young CR, Black RE, Lim Y-L, Robins-Browne RM, 1982. Magnitude, kinetics and duration of vibriocidal antibody response in North Americans after ingestion of Vibrio cholerae. J Infect Dis 145: 465-473.
13. Levine MM, Young CR, Black RE, Takeda Y, Finkelstein RA, 1985. Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains and to cholera toxin: application in serodiagnosis and seroepidemiology. J Clin Microbiol 21: 174-179.
14. Van de Verg L, Herrington DA, Murphy JR, Wasserman SS, Formal SB, Levine MM, 1990. Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi -Shigella sonnei vaccine or infection by pathogenic S. sonnei. Infect Immun 58: 2002-2004.
15. Losonsky G, Yunyongying J, Lim V, Reymann M, Lim YL, Wasserman SS, Levine MM, 1996. Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. Infect Immun 64: 10-15.
16. Levine MM, Kaper JB, Herrington DA, Losonsky GA, Morris JG, Clements ML, Black RE, Tall BD, Hall R, 1988. Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect Immun 56: 161-167.
17. Herrington DA, Hall RH, Losonsky GA, Mekalanos JJ, Taylor RK, Levine MM, 1988. Toxin, toxin-regulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med 168: 1487-1492.